The total return over the past 12 months is -23.14% vs. +16.94% for the S&P 500. So far it's up -13.74% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (23.14%) | (67.53%) | (58.32%) | (57.48%) | N/A | N/A |
| Total Return CAGR | (23.14%) | (67.53%) | (58.32%) | (57.48%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Indaptus Therapeutics, Inc. (INDP)
| Year | Start price | End price | INDP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $2.91 | $2.51 | (13.74%) | +14.51% | (28.25%) |
| 2025 | $23.58 | $2.91 | (87.66%) | +17.72% | (105.38%) |
| 2024 | $49.28 | $23.58 | (52.15%) | +24.89% | (77.04%) |
| 2023 | $40.60 | $49.28 | +21.38% | +26.19% | (4.81%) |
| 2022 | $159.60 | $40.60 | (74.56%) | (18.17%) | (56.39%) |
| 2021 | $386.40 | $159.60 | (58.70%) | +28.74% | (87.44%) |
| 2020 | $1,120.00 | $386.40 | (65.50%) | +18.37% | (83.87%) |
| 2019 | $16,889.60 | $1,120.00 | (93.37%) | +31.22% | (124.59%) |
| 2018 | $11,536.00 | $16,889.60 | +46.41% | (4.56%) | +50.97% |
| 2017 | $12,768.00 | $11,536.00 | (9.65%) | +21.70% | (31.35%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
